Interim analysis of a double blind study of Ovarex™ mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. - Berek,J.; Ehlen,T.; Gordon,A.; Nicodemus,C.; Schultes,B.; Whiteside,T.; Noujaim,A. (Proc Am Soc Clin Oncol, 2001)